”We are impressed by Ascilion’s technology platform and by the team behind the company. Ascilion’s products are at the forefront and can contribute to developing and improving today’s diagnostic methods. Nordstjernan’s ambition is to continue growing in the health sector, and medical technology and diagnostics are areas we actively want to invest in. We look forward to supporting Ascilion in the company’s future development,” says Nordstjernan’s CEO Peter Hofvenstam.
STOCKHOLM, SWEDEN – Ascilion AB ("Ascilion") the leader in dermal interstitial fluid sampling for biomarker investigation announced today that the first patient has been enrolled in the DIGIPREDICT-Bio-DE study at the Deutsches Herzzentrum der Charité ("DHZC") in Berlin, Germany.
Ascilion´s microneedle technology is used to extract dermal interstitial fluid (dISF), the fluid between cells in the skin. This fluid is rich in biomarkers, some of which are unique, and is a previously untapped source of health information.
Part of the pan-European DIGIPREDICT program, the study utilizes Ascilion´s technology to sample dISF, that is then used to validate a sensor platform developed to detect biomarkers relevant to cytokine storms and cardiovascular disease.
Last week the first ambulatory heart-failure patient was enrolled in the study at DHZC. The subject performed a cardiopulmonary exercise test (CPET) and both blood and dISF were sampled. By comparing biomarker concentrations in dISF and blood, biomarker sensors can be validated, and biomarker dynamics in dISF evaluated.
Dr Laurenz Kopp Fernandes, Senior Physician at DHZC, commented: “The ability to sample dermal interstitial fluid means we now have really minimally-invasive access to established as well as to probably new biomarkers, which will potentially change the management of our patients. We are only now learning about how valuable the biomarker information contained in dISF can be. The enrollment of the first patient is an important step towards their investigation, and I am looking forward to the new insights we will gather in this important study.”
Simon Grant, CEO of Ascilion commented: ‘This project illustrates the potential for dISF sampling to take a central role within patient monitoring and management. Today, Ascilion has established relationships with global leaders in several industry segments. At the same time we have seen an increase in interest over the last 18 months that has been remarkable as researchers and industry learn about dISF and our technology.’
This project has received funding from the European Union’s Horizon 2020research and innovation programme under grant agreement No 101017915(DIGIPREDICT). www.digipredict.eu
For further information visit www.ascilion.com or contact:
Simon Grant, CEO
Tel: +46 72 887 43 99
E-post: info@ascilion.com
About Ascilion
Ascilion is the world leader in sampling of dermal interstitial fluid (dISF). A pioneer within hollow microneedle technology, Ascilion has developed the only solution available for sampling of practical amounts of pure dISF, enabling complete quantitative biomarker evaluation. Ascilion’s product PELSA is painless, quick, easy to use and leaves no residual mark on the skin. PELSA is available for research use and for pharmaceutical or cosmetic testing applications and is currently undergoing the medical product approval process. We are a cross-functional team based just outside Stockholm, Sweden and currently work with selected industrial partners and researchers.
About DIGIPREDICT
DIGIPREDICT – Digital Edge AI-deployed DIGItal Twins for PREDICTing disease progression and need for early intervention in infectious and cardiovascular diseases beyond COVID-19.
DIGIPREDICT is a pan-European research program bringing together scientific and technical excellence in multiple disciplines including informatics, engineering (embedded systems,sensors and wearables), medical science, translational science, ethical and regulatory frameworks. The consortium consists of in total nine members from academia, two large R&D institutes, two hospitals, three high-tech SMEs from five European countries. The project will develop Digital Twins to enable identification, monitoring, and screening of high-risk patients, and to provide them with the right supportive therapy based on referral decisions that can be personalized. A digital twin is a digital representation of an object or process from the real world in the digital world – and more specifically for the case of DIGIPREDICT – of a patient.
DIGIPREDICT will also develop wearables for early detection of infectious and cardiovascular diseases.
STOCKHOLM, SWEDEN – Ascilion AB ("Ascilion") the leader in dermal interstitial fluid sampling, announced today that Ascilion’s technology received the highest possible rating for both Market Creation Potential and Market Readiness from the European Commission’s Innovation Radar group.
Ascilion´s microneedle technology is used to extract dermal interstitial fluid, the fluid between cells in the skin. This fluid is rich in biomarkers, some of which are unique, and is a previously untapped source of health information. Today, Ascilion works with global leaders in several industry segments to access and utilize this information.
As an essential part of the EU-funded pan-European DIGIPREDICT program, Ascilion has provided the sampling technology for the project. The Innovation project is titled ‘Minimal invasive system for dermal interstitial fluid (dISF) sampling and collection’.
Of the nearly 12,000 projects evaluated to date by the EU Innovation group, only 152 have received this highest level of evaluation, placing Ascilion in the top 1% of projects funded by EU. The evaluation is made up of two parts: Market creation potential and Market maturity.
Market creation potential was judged to be ’Very High’, the highest grade, and is an indication of the potential commercial impact the technology and products can have on the market. Market maturity was judged as ‘Market Ready’ which indicates that the products are ready to market, now.
Simon Grant, CEO of Ascilion commented: ‘We are extremely pleased that the EU has understood the potential and implications of our technology, and also how far the team has come with the products. To receive the highest rating in one classification is an achievement, to receive it in both is very rare. We believe that the potential for our products is broad and that they can open entirely new and exciting possibilities within monitoring and diagnostics that create significant value for industry while helping patients and consumers.’
The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No101017915 (DIGIPREDICT). www.digipredict.eu
For further information visit www.ascilion.com or contact:
Simon Grant, CEO
Tel: +46 72 887 43 99
E-post: info@ascilion.com
For the third time Ascilion’s dermal ISF sampling solutions were presented at the annual meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) in Germany.
This year, researchers from the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, and Institute of Allergology (IA), Charité - Universitätsmedizin Berlin, presented the application of Ascilion’s hollow microneedles in a model of chronic inducible urticaria.
Read the abstract (on page 7):P014 - 15.1 “Application of hollow microneedles in a model of chronic inducible urticaria” (Shi et al. 2024)
Ascilion ADF abstracts from 2024 and previous years can be found here: ADF Abstract Books
Ascilion will attend and exhibit at the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Disease in Boston. The meeting will be held from the 31st October - 2nd November 2023
The conference is specifically for executives from pharmaceutical companies working within drug development in the inflammatory skin disease area. This will be an excellent opportunity for Ascilion to discuss how it's dermal interstitial fluid (dISF) sampling technology can assist pharma companies in their development processes.
For more information on the conference: https://ter.li/b201q6
STOCKHOLM, SWEDEN, October 3, 2023 /EINPresswire.com/ -- Ascilion AB ("Ascilion") the world leader in interstitial fluid (ISF) sampling for biomarker investigation announced yesterday that the Board has appointed Simon Grant as Chief Executive Officer (CEO).
Simon has extensive Life Science industry experience, having held management positions in smaller startups such as Neoventa and Synectics Medical, and large multinationals such as Medtronic and Sandvik. Most recently Simon held the position of CEO at SciBase AB, a Swedish point-of-care diagnostics company listed on Nasdaq First North, Stockholm.
Sten Dahlborg, Chairman of the Board at Ascilion commented: "We are very happy to welcome Simon as CEO, and his appointment signals a new phase in the development of Ascilion. Simon brings extensive commercialization experience, having developed and introduced more than a dozen new medical technologies in the international market. His enthusiasm towards our technology and its application reinforces our belief in its potential" Furthermore, he added: "I would also like to take the opportunity to thank Markus Renlund for the excellent work he has done to lead the company to this stage. Markus will continue with the Company, both as a Board member and in his role as Technology and Innovation Lead.
Simon Grant commented "In my opinion interstitial fluid sampling has the potential to disrupt the standard of care in multiple clinical specialties and drive significant research and wellness applications. ISF contains a ‘treasure trove’ of biomarker information that until now has been mostly untapped because it is practically so difficult to extract. Ascilion is a world leader in hollow microneedles, and it is that technology that enables us to access ISF in useful volumes for the very first time. I believe that Ascilion has the ability to change the way that things are done clinically and that we can build a significant business around the technology – and this is especially exciting for me.”
For further information visit www.ascilion.com or contact:
Sten Dahlborg, Chairman
Tel: +46 70 836 94 19
or
Simon Grant, CEO
Tel: +46 72 887 43 99
E-post: info@ascilion.com
About Ascilion
Ascilion is the world leader in sampling of dermal interstitial fluid (dISF). A pioneer within hollow microneedle technology since 2012, Ascilion has developed the only solution available for sampling of practical amounts of pure dISF, enabling complete quantitative biomarker evaluation. Ascilion’s technology is painless, quick, easy to use and leaves no residual mark on the skin. Products are available for research use and for pharmaceutical or cosmetic testing applications and are currently undergoing the medical product approval process. We are a cross-functional team based just outside Stockholm, Sweden working closely with industry-leading customers in several target segments.
Ascilion is pleased to participate in a study at IFA, Charité where part of the study aims to confirm that sub-pressure assisted interstitial fluid (ISF) extraction using hollow microneedles reliably and repeatability yields sufficient volumes of ISF for tryptase, histamine determination and cytokine profiling in response to skin provocation.
The International Microneedle Conference is a global conference comprised of both industrial and academic attendees, and this event has grown steadily since its inception in 2010.
Ascilion is proud to announce its support to the conference by being a Gold Sponsor.
Come and meet part of the Ascilion team at the MICRONEEDLES conference, Hyatt At Olive 8, 1635 8th Ave, Seattle, USA between May 15 – May 17, 2023
Presentations and live demonstration of interstitial fluid sampling was held by Ascilion during the 5th Consortium Meeting in the European Project DIGIPREDICT was held at EPFL, Lausanne Switzerland.
Representatives from Charité – Universitätsmedizin Berlin and Fraunhofer Institute for Translational Medicine and Pharmacology will present “Application of hollow microneedles for skin ISF harvesting in models of allergy and chronic urticaria”at the 9th International Microdialysis Symposium, 7-9 September, 2022, Berlin, Germany
Nordstjernan is investing in Ascilion, a Swedish medtech company founded in 2012 and based in Stockholm, Sweden. Ascilion has developed and patented a technology that uses an array of hollow microneedles to extract the interstitial fluid (ISF) that surrounds the body’s cells and that is a good carrier of biomarkers. Ascilion’s technology has numerous fields of application, including within several branches of medical diagnostics. Nordstjernan will become the second largest owner in Ascilion and, as a partner to the company’s founder and current owners, the aim is to accelerate the company’s commercial development.
“We are impressed by Ascilion’s technology platform and by the team behind the company. Ascilion’s products are at the leading edge and can help develop and improve current diagnostic methods. Nordstjernan’s ambition is to continue growing in the health sector, and medtech and diagnostics are fields in which we want to actively invest. We look forward to supporting Ascilion in the company’s future development,”
says Nordstjernan’s CEO Peter Hofvenstam.
DIGIPREDICT is a pan-European research program bringing together scientific and technical excellence in multiple disciplines including informatics (machine learning), engineering (embedded systems, sensors, and wearables), medical science (organ-on-chip systems, digital medicine), translational science (clinical studies and research), ethical and regulatory frameworks. The consortium consists of three members from academia (EPFL, UTWENTE & ETHZ), two large R&D institutes (IMEC-BE & IMEC-NL), two hospitals (Charité & UBERN), two high-tech SMEs (Ascilion and EPOS) and a management and communication SME (SCIPROM) from five European countries.
Ascilion´s role in the project will be to design and manufacture chips with arrays of ultra-sharp, hollow microneedles in monocrystalline silicon using micro-electro-mechanical system (MEMS) technology.
The DIGIPREDICT, funded by the European Union's Horizon 2020 research and innovation programme, started on 1 January 2021 and will run until 31 December 2024
Presentations: “Interstitial Fluid Extracted using Hollow Microneedles - Comparison of Lipid Content in ISF vs Whole Blood”, “Sub-pressure Assisted Application of Sharp Hollow Microneedles Improves Penetration”.
Presentation: “Rapid Extraction of Interstitial Fluid using Sharp Hollow Silicon Microneedles”
Presentation: “High-yield and High-volume Fabrication of Silicon Microneedles Intended for Interstitial Fluid Extraction”
Presentation: “Extraction of Interstitial Fluid and Sensing of Glucose Levels using Microneedles and Millimetre Wave Spectroscopy”
